Lars Fruergaard Jørgensen, who led the Danish pharmaceutical giant since 2017, is leaving his post due to growing competition from rival Eli Lilly and declining company shares. The decision comes as Novo Nordisk faces market challenges, with its share price tumbling by 27% in March and forecasts being revised downward. Jørgensen will remain CEO while the company searches for his successor to ensure a smooth transition. He first joined the firm in 1991, rising to top executive in 2017.
Source: https://www.euronews.com/health/2025/05/16/polio-outbreak-declared-in-papua-new-guinea-spurring-preparation-for-vaccination-campaign